[Skip to Content]
[Skip to Content Landing]
September 13, 1993

Infectious Complications in Heart-Lung Transplantation: Analysis of 200 Episodes

Author Affiliations

From the Departments of Medicine (Drs Kramer, Marshall, Amitai, and Theodore) and Cardiovascular Surgery (Dr Starnes and Ms Gamberg), Stanford (Calif) University School of Medicine.

Arch Intern Med. 1993;153(17):2010-2016. doi:10.1001/archinte.1993.00410170090009

Background:  Infection remains an important cause of morbidity and mortality in heart-lung transplant recipients. This study was designed to assess the frequency, type, and timing of infection in heart-lung transplant recipients.

Methods:  A retrospective analysis of 200 episodes of serious infections occurring in 73 heart-lung recipients at Stanford (Calif) University Medical Center between 1981 and 1990.

Results:  Bacterial infections accounted for half of all infections, with the highest incidence in the first month after transplantation. Fungal infections (14%) were also common in the first month. Cytomegalovirus was the most common viral agent (15%), occurring primarily in the second month after transplantation. Other viruses (herpes simplex, adenovirus, and respiratory syncytial virus) accounted for a further 15% of total infections. Pneumocystis carinii infections were common 4 to 6 months after transplantation, and Nocardia typically infected recipients later than 1 year after transplantation. There was no significant difference in incidence of infections between patients receiving triple (cyclosporine, prednisone, immuran) or double (cyclosporine and prednisone) immunosuppression therapy. Mortality due to infection accounted for 40% of all deaths.

Conclusions:  Knowledge of the incidence and timing of infection should help in the prevention, early detection, and initiation of therapy in these patients.(Arch Intern Med. 1993;153:2010-2016)

Dummer JS.  Infectious complication in transplantation . In: Thompson ME, ed.  Cardiac Transplantation . Philadelphia, Pa: FA Davis Co Publishers; 1990:163-175.
Brooks RG, Hofflin JM, Jamison SW, Stinson EB, Remington JS.  Infectious complications in heart-lung transplant recipients .  Am J Med. 1985;79:412-418.Crossref
Dummer JS, Montero CG, Griffith BP, Hardesty RL, Paradis IL, Ho M.  Infections in heart-lung transplant recipients .  Transplantation . 1986;41:725-729.Crossref
Penketh AR, Higgenbottam TW, Hutter J, Coutts C, Stewart S, Wallwark J.  Clinical experience in the management of pulmonary opportunistic infection and rejection in recipients of heart-lung transplants .  Thorax. 1988;43:762-769.Crossref
Starnes VA, Theodore J, Oyer P, et al.  Evaluation of heart-lung transplant recipients with prospective serial transbronchial biopsies and pulmonary function studies .  J Thorac Cardiovasc Surg. 1989;98:683-690.
Starnes VA, Theodore J, Oyer P, et al.  Pulmonary infiltrates after heart-lung transplantation: evaluation by serial transbronchial biopsies .  J Thorac Cardiovasc Surg. 1989;98:945-950.
Lewiston NJ, Marshall SE, Kramer MR, Sibley R, Starnes VA, Theodore J.  Prospective analysis of serial pulmonary function studies and transbronchial biopsies in single lung transplant recipients .  Transplant Proc. 1991:23:1217-1219.
Ho M, Wajszczuk CP, Hardy A, et al.  Infection in kidney, heart, and liver transplant recipients on cyclosporin .  Transplant Proc. 1983;15:2768-2772.
Higgenbottam T, Jackson M, Woolman P, Lowery R, Wallwark J.  The cough response to ultrasonically nebulized distilled water in heart-lung transplant patients .  Am Rev Respir Dis. 1989;140:58-61.Crossref
Shankar S, Fulsham L, Aravot D, Read RC, Madden B.  Mucociliary function after lung transplantation .  Transplant Proc. 1991;23:1222-1223.
Glanville A, Burke C, Theodore J, et al.  Bronchial hyper-responsiveness after human cardiopulmonary transplantation .  Clin Sci. 1987;73:299-303.
Patterson GA, Todd TR, Cooper JD, et al.  Airway complications after double lung transplantation .  J Thorac Cardiovasc Surg. 1990;99:14-21.
Mason JW, Stinson EB, Hunt SA, Schroeder JS, Rider AK.  Infections after cardiac transplantation: relation to rejection therapy .  Ann Intern Med. 1976;85: 69-74.Crossref
Lewiston N, King V, Umetsu D, et al.  Cystic fibrosis patients who have undergone heart-lung transplantation benefit from maxillary sinus antrostomy and repeated sinus lavage .  Transplant Proc. 1991;23:1207-1208.
Theodore J, Starnes VA, Lewiston NJ.  Obliterative bronchiolitis .  Clin Chest Med. 1990;11:309-321.
Glanville AR, Baldwin JC, Burke CM, Theodore J, Robin ED.  Obliterative bronchiolitis after heart-lung transplantation: apparent arrest by augmented immunosuppression .  Ann Intern Med. 1987;107:300-304.Crossref
Kusne S, Dummer JS, Singh N, et al.  Infection after liver transplantation: an analysis of 101 consecutive cases .  Medicine . 1988;67:132-143.Crossref
Steffenson DO, Dummer JS, Granick MS, Pasculle AW, Griffith BP, Cassell GH.  Sternotomy infections with Mycoplasma hominis .  Ann Intern Med. 1987;106: 204-208.Crossref
Trulock EP, Bolman RM, Genton R.  Pulmonary disease caused by Mycobacterium chelonae in a heart-lung transplant recipient with obliterative bronchiolitis .  Am Rev Respir Dis. 1989;140:802-805.Crossref
Burke CM, Glanville A, Macoviac M, et al.  The spectrum of CMV infection following human heart-lung transplantation .  Chest . 1984;86:824-829.Crossref
Dummer JS, White LT, Ho M, et al.  Morbidity of cytomegalovirus infection in recipients of heart or heart-lung transplants who receive cyclosporine .  J Infect Dis. 1985;152:1182-1186.Crossref
Rand KH, Pollard RB, Merigan TC.  Increased pulmonary superinfections in cardiac transplants undergoing primary cytomegalovirus infection .  N Engl J Med. 1978;298:951-956.Crossref
Erice A, Jordan MC, Chace BA, Fletcher C, Chinnock BJ, Balfour HH Jr.  Ganciclovir treatment of cytomegalovirus disease in transplant recipients and other immunocompromised hosts .  JAMA . 1987;257:3082-3087.Crossref
Snydman DR, Werner BG, Heinze-Lacey B, et al.  Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients .  N Engl J Med. 1987;317:1049-1054.Crossref
Hanto DW, Gajl-Peczalska KJ, Frizzera G, et al.  Epstein-Barr virus (EBV) induced polyclonal and monoclonal B-cell lymphoproliferative diseases occurring after renal transplantation: clinical, pathologic, and virologic findings and implications for therapy .  Ann Surg. 1983;198:356-369.Crossref
Starzl TE, Nalesnik MA, Porter KA, et al.  Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy .  Lancet . 1984;1:583-587.Crossref
Kramer MR, Denning DW, Marshall SE, et al.  Ulcerative tracheobronchitis following lung transplantation: a new form of invasive aspergillosis .  Am Rev Respir Dis. 1991;144:552-556.Crossref
Faggian G, Livi U, Bortolotti U, et al.  Itraconazole therapy for acute invasive pulmonary aspergillosis in heart transplantation .  Transplant Proc. 1989;21: 2506-2507.
Kramer R, Marshall SE, Denning D, et al.  Interaction between cyclosporin and itraconazole in heart and lung transplant recipients .  Ann Intern Med. 1990; 113:327-329.Crossref
Gryzan S, Paradis IL, Zeevi A, et al.  Unexpected high incidence of Pneumocystis carinii infection in heart-lung transplantation .  Am Rev Respir Dis. 1988; 137:1268-1274.Crossref
Dummer JS.  Pneumocystis carinii infections in transplant recipients .  Semin Respir Infect. 1990;1:50-57.
Hughes WT, Rivera GK, Schell MJ, Thornton D, Lott L.  Successful intermittent chemoprophylaxis of Pneumocystis carinii pneumonitis .  N Engl J Med. 1987; 316:1627-1632.Crossref
Kramer MR, Stoehr C, Lewiston NJ, Starnes VA, Theodore J.  Trimethoprimsulfamethoxazole prophylaxis for Pneumocystis carinii infection in lung transplantation: how effective and for how long .  Transplantation . 1992;53:586-589.Crossref
Wreghitt TG, Hakim M, Cory PR, English THA, Wallwark J.  The impact of donor transmittent CMV and Toxoplasma gondii disease in cardiac transplantation .  Transplant Proc. 1986;18:1375-1376.
Simpson GL, Stinson EB, Eggar MJ, Remington JS.  Nocardial infections in the immunocompromised host: a detailed study in a defined population .  Rev Infect Dis. 1981:3:492-507.Crossref